An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.Hormone research in paediatrics · 2024
   Guideline
2. Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities.International journal of molecular sciences · 2023
   Review
3. Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.Frontiers in immunology · 2023
   Review
4. Lessons from Human Islet Transplantation Inform Stem Cell-Based Approaches in the Treatment of Diabetes.Frontiers in endocrinology · 2021
   Review

Corrections and comments

• Erratum for
  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.2019

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.